[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"insulinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:insulinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,73,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":4,"leadSponsor":36,"locationsCount":39},"100054339","diagnosing-and-treating-low-blood-sugar-levels-100054339",false,"NCT00001276","Diagnosing and Treating Low Blood Sugar Levels","Fasting Hypoglycemia: Diagnosis and Treatment","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Male, females ages \\>= 18.\n2. Patients with documented fasting blood glucose below 55 mg\u002Fdl.\n\n4\\. Patients with biochemical evidence for insulinoma or other pancreatic neuroendocrine tumors.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Patients with significant cardiac disease will be excluded.\n2. Subjects who are pregnant per self-report.\n3. Medically unstable per the assessment of the PI.","ALL","18 Years","120 Years",{"count":20,"type":21},1500,"ESTIMATED","OBSERVATIONAL","Hypoglycemia is the term used to refer to lower than normal levels of blood sugar. This study will continue to research the causes of hypoglycemia.\n\nPatients involved in the study will be admitted to the Clinical Center of the National Institutes of Health and undergo tests for evaluating blood sugar. Patients will be required to refrain from eating for a set period of time and will undergo blood tests for insulin levels and several other specific diagnostic tests related to insulin secretion. The patients will be under supervision and will be provided with appropriate medical and surgical attention as needed.",[25,26],"Hypoglycemia","Insulinoma",[25,26,28],"Natural History","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"1991-05-21",{"name":37,"class":38},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":47,"phases":4,"briefSummary":48,"conditions":49,"keywords":52,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":70,"locationsCount":39},"100202772","18f-l-fluoro-dopa-petct-scan-localization-of-focal-pancreatic-lesions-in-subjects-with-hyperinsulinemic-hypoglycemia-100202772","NCT01916148","18F-L-Fluoro-DOPA PET\u002FCT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia","Expanded Access Use of 18F-L-Fluoro-DOPA PET\u002FCT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia","Inclusion Criteria:\n\n* Subjects of any age with hyperinsulinemic hypoglycemia, diagnosed by a fasting test and\u002For response to glucagon stimulation.\n* Subjects who are eligible for pancreatic surgery regardless of prior pancreatic surgery\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Any other major illness or condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in this study\n* Subjects who are not a candidate for pancreatic surgery","EXPANDED_ACCESS","This purpose of this study is to determine the ability of an 18F-fluoro-L-dihydroxyphenylalanine (18F-DOPA) PET (Positron Emission Tomography) scan to detect a focal lesion of hyperinsulinism and determine the location in patients with congenital hyperinsulinism, Beckwith Wiedemann Syndrome and suspected insulinoma. Safety data will be collected.",[50,51,26],"Congenital Hyperinsulinism (CHI)","Beckwith-Wiedemann Syndrome",[25,53,54,55,56,57,58,59,60,61,62,63,64,65],"Hyperinsulinism (HI)","F-DOPA","PET","18-F DOPA","18F-L-Fluoro-DOPA","18F-fluoro-L-dihydroxyphenylalanine","focal pancreatic lesions","congenital hyperinsulinism","Beckwith Wiedemann Syndrome","insulinoma","Hyperinsulinemic Hypoglycemia","F-DOPA PET","CHI (Congenital hyperinsulinism)","AVAILABLE","2026-04-22",{"date":69,"type":33},"2026-04-27",{"name":71,"class":72},"Children's Hospital of Philadelphia","OTHER",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":83,"studyType":22,"phases":4,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":39},"100571856","glucagon-like-peptide-1-receptor-petct-in-glp-1r-related-disease-100571856","NCT06725693","Glucagon-like Peptide-1 Receptor PET\u002FCT in GLP-1R Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"80 Years",{"count":82,"type":21},500,"7 Days","To evaluate the potential usefulness of 68Ga\u002F18F-Exendin 4 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.",[86,87,26,88],"GLP1-R-related Disease","Tumor","Positron Emission Tomography",[90,91],"PET\u002FCT","GLP1-R","2025-02-07",{"date":94,"type":33},"2025-02-11",{"date":96,"type":33},"2019-02-01",{"date":98,"type":21},"2027-11-01",{"name":100,"class":72},"Tianjin Medical University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":39},"100210840","phase-1-fluorodopa-f-18-in-congenital-hyperinsulinism-and-insulinoma-100210840","NCT02021604","Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma","The Use of Fluorodopa F 18 Positron Emission Tomography Combined With Computed Tomography in Congenital Hyperinsulinism and Insulinoma","Inclusion Criteria:\n\n* Patients with HI attending the Cook Children's Congenital Hyperinsulinism Center and being treated by an Endocrinologist which may be the PI or a partner of this clinician.\n* The patient's Endocrinologist has determined that the patient cannot be safely managed with standard medical therapy (failed) and surgery is recommended to prevent future episodes of severe hypoglycemia and preserve brain function. Failure of medical therapy is defined as both:\n\n  * Hypoglycemia (blood glucose \\\u003C70 m\u002FdL) on a single measure despite the use of anti-hypoglycemic medications, if applicable to the individual patient, including and limited to diazoxide or octreotide\n  * Inability to fast, defined as the inability to maintain a blood glucose \\>50 mg\u002FdL for: 1) more than 12 hours for infants \\\u003C 1 year of age; 2) more than 15 hours 1-3 years of age; 3) more than 18 hours over 3 years of age\n* Patients in whom the genetic testing (if available and informative) does not prove diffuse HI disease. Such children might be considered if they have one or more of the following situations:\n\n  * no genetic testing results (e.g., due to insurance denial or parental refusal)\n  * negative genetic testing (note: only 75% of mutations may be found with existing technology)\n  * no autosomal recessive mutations in ABCC8 or KCNJ11 on the maternal allele\n  * no autosomal dominant mutations in ABCC8 or KCNJ11\n* Patients thought to have focal HI disease based on genetic testing or insulinoma based on clinical evaluation and have well-controlled blood glucose levels with any degree of dietary or medical management, BUT the patient and their parent(s) or LAR wishes to proceed with surgery for a possible cure of HI disease.\n\nExclusion Criteria:\n\n* Patients who do not have a diagnosis of HI\n* Patients with genetic evidence of diffuse HI\n* Patients who are pregnant\n* Nursing mothers who are unwilling to discontinue breastfeeding their infant for 48 hours after Fluorodopa F 18 injection\n* Patients with a known allergy to Fluorodopa F 18 agent",{"count":109,"type":21},250,"INTERVENTIONAL",[112],"PHASE1","Low blood sugars are known to cause brain damage in newborn babies. One of the most common causes of low blood sugars persisting beyond the new born period is a condition called congenital hyperinsulinism (HI). This is a disease whereby the pancreas secretes too much insulin and causes low blood sugars. Twenty to forty percent of these babies will have brain damage. There are two forms of this disease. In one form only a small part of the pancreas makes too much insulin (focal HI) and in the other, the whole pancreas make too much insulin (diffuse HI). Another very similar disease is insulinoma which occurs after birth, but also causes hyperinsulinism. If a surgeon could know which part of the pancreas has the focal lesion he could remove it and cure the patient.\n\nThe purpose of this study is to investigate whether a new investigational drug called Fluorodopa F 18, when used with a PET scan, can find the focal lesion and guide the surgeon to remove it, thus curing the patient and preventing further brain damage.",[115,26],"Congenital Hyperinsulinism",[115,117,25,118,119,120,26],"HI","FDOPA","18F-DOPA","Hyperinsulinism","2024-07-15",{"date":123,"type":33},"2024-07-16",{"date":125,"type":33},"2013-10-09",{"date":127,"type":21},"2028-06",{"name":129,"class":72},"Cook Children's Health Care System"]